Related Experiment Video
Updated: Jul 12, 2026
Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
Recognition and management of macrophage activation syndrome in juvenile arthritis
Alison Kelly1, Athimalaipet V Ramanan
1Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol and Royal National Hospital for Rheumatic Diseases, Bath, UK.
Insights
Macrophage activation syndrome (MAS) is a severe complication in children with systemic onset juvenile idiopathic arthritis (sJIA). Recent developments in diagnosis, pathogenesis, and management are reviewed to improve patient outcomes.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Internal Medicine
Background:
- Macrophage activation syndrome (MAS) is a life-threatening complication.
- It is predominantly seen in children with systemic onset juvenile idiopathic arthritis (sJIA).
- MAS significantly contributes to the morbidity and mortality in sJIA patients.
Purpose of the Study:
- To review recent developments in the diagnosis of MAS in sJIA.
- To discuss new insights into the classification and pathogenesis of MAS.
- To explore advancements in the management of MAS in sJIA.
Main Methods:
- Literature review of recent studies on MAS in sJIA.
- Analysis of new diagnostic criteria and classification systems.
- Evaluation of current and emerging therapeutic strategies.
Main Results:
- The review highlights new diagnostic and classification criteria for MAS in sJIA.
- Recent findings on the pathogenesis of MAS provide a deeper understanding of the disease.
- Current management strategies and potential new treatments are discussed.
Conclusions:
- Further research into the pathophysiology of MAS in sJIA is essential.
- Improved understanding will lead to more sensitive diagnostic criteria.
- Enhanced knowledge will facilitate better management strategies for MAS in sJIA.
Purpose Of Review:
Macrophage activation syndrome is a life-threatening complication seen predominantly in children with systemic onset juvenile idiopathic arthritis. It accounts for a significant amount of the morbidity and mortality seen with systemic onset juvenile idiopathic arthritis.
Recent Findings:
In this article, we will look at the new developments in the diagnosis, classification, pathogenesis and management of macrophage activation syndrome in systemic onset juvenile idiopathic arthritis patients.
Summary:
More work is needed to further elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenile idiopathic arthritis. This would be the key to early diagnosis using more sensitive criteria and better management.